Skip to main
AIM
AIM logo

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech Inc. has demonstrated a consistent trend of positive data from clinical studies, particularly highlighting its flagship product, Ampligen, in various therapeutic applications. Notably, the successful results from a Phase 2a study assessing Ampligen for colorectal cancer and a Phase 2 study for post-COVID conditions bolster the company's position in the immuno-pharma sector. These encouraging outcomes not only validate the efficacy of Ampligen but also have the potential to serve as significant catalysts for future stock performance.

Bears say

AIM ImmunoTech Inc. reported a net loss of $2.8 million, equating to an earnings per share (EPS) of $(3.68), which fell short of estimates of $(8.00). The company faces several risks that jeopardize its financial outlook, including balance sheet and liquidity challenges, the potential failure of key product candidates to demonstrate safety and efficacy in clinical trials, and hurdles in gaining regulatory approvals. Additionally, the ability to commercialize its products effectively, secure suitable reimbursement, and navigate competitive and macroeconomic landscapes further compounds the negative outlook for the stock.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.